Molina Healthcare
MOH
$147.51
-1.65%
Molina Healthcare, Inc. is a managed care company providing government-sponsored healthcare programs, primarily through Medicaid, Medicare, and individual Marketplace plans. The company is a significant player in the Medicaid space, with over 85% of its more than 5 million members enrolled through state contracts, establishing it as a specialized, government-focused insurer. The current investor narrative is dominated by the company's recent severe profitability challenges, highlighted by a significant Q4 2025 net loss, which has triggered a sharp stock price decline and intense scrutiny over its medical cost management and the sustainability of its margins in a competitive and regulated environment.…
MOH
Molina Healthcare
$147.51
MOH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $191.76 and implied upside of +30.0% versus the current price.
Average Target
$191.76
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$118 - $192
Analyst target range
Analyst coverage consists of 7 firms, and recent institutional ratings show a cautious to negative tilt, with actions including a downgrade from Wells Fargo to 'Equal Weight' and maintained 'Underweight' and 'Neutral' stances from others. The consensus sentiment is neutral at best, leaning bearish, given the lack of 'Buy' ratings in recent actions and the prevalence of 'Hold' and 'Underweight' calls. While a specific average target price is not provided in the data, the estimated EPS average for the next period is $25.38, but deriving an implied price from this is not possible without a target multiple. The target range from the estimated revenue data suggests high uncertainty, with a low estimate of $49.99 billion and a high of $56.22 billion for future revenue. The wide spread between these estimates, coupled with the recent downgrades, signals low conviction and high uncertainty among analysts regarding the company's near-term financial trajectory and its ability to recover from the Q4 2025 loss.
Bulls vs Bears: MOH Investment Factors
The bear case currently holds stronger evidence, anchored by the severe and sudden collapse in profitability and cash generation in Q4 2025. The dramatic swing from substantial profit to a significant net loss, coupled with negative free cash flow, points to a fundamental operational crisis that outweighs the compelling valuation argument. The single most important tension in the investment debate is whether the Q4 collapse represents a one-time, correctable misstep in medical cost management or a structural impairment of Molina's ability to profitably administer its government contracts. The resolution of this tension—evidenced by a return to positive net income and operating cash flow in subsequent quarters—will determine if the stock is a deep value trap or a turnaround opportunity.
Bullish
- Extremely Low Valuation on Sales: The stock trades at a trailing Price-to-Sales ratio of just 0.194, an extreme discount that historically signals deep value. This valuation is near the bottom of its multi-year range, having compressed from levels above 2.0, suggesting a severe market overreaction to recent negative news.
- Strong Revenue Base and Growth: Despite profitability issues, the company maintains a massive revenue base of over $11 billion per quarter, with Q4 2025 revenue still showing 8.34% year-over-year growth. This demonstrates underlying demand for its government-sponsored healthcare plans and a resilient core business.
- Significant Cash Buffer: The company reported a cash balance of $4.25 billion, providing a substantial cushion to navigate the current profitability crisis. This liquidity supports the company's ability to fund operations and invest in corrective measures without an immediate solvency threat.
- Sector Tailwind from CMS Policy: Recent news indicates a larger-than-expected 2027 Medicare Advantage payment increase from CMS, which is a positive sector-wide catalyst. As a managed care company, Molina could benefit from improved revenue visibility and sentiment if it can stabilize its operations.
Bearish
- Severe Profitability Collapse: Q4 2025 net income swung to a loss of -$160 million from a profit of $298 million in Q1 2025, representing a dramatic deterioration. Gross margin collapsed to 6.16% in Q4 from 11.48% in Q1, indicating a fundamental breakdown in medical cost management.
- Persistent Negative Cash Flow: The company generated negative free cash flow of -$636 million on a TTM basis and negative operating cash flow of -$298 million in Q4 2025. This cash burn, despite a large cash balance, raises serious questions about the sustainability of the business model in its current state.
- Analyst Downgrades and Low Conviction: Recent analyst actions include a downgrade to 'Equal Weight' and maintained 'Underweight' and 'Neutral' ratings, reflecting a cautious to negative institutional view. The wide range of estimated future revenue ($49.99B to $56.22B) signals high uncertainty and low consensus on a recovery path.
- Debt and Deteriorating Balance Sheet: While the current ratio of 1.69 shows short-term liquidity, the debt-to-equity ratio of 0.97 indicates moderate leverage. The combination of rising debt, negative earnings, and cash burn pressures the financial structure, increasing refinancing and operational risks.
MOH Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -57.43%, significantly underperforming the broader market. The current price of $145.88 sits near the bottom of its 52-week range, trading at approximately 10% above its 52-week low of $121.06, which suggests the stock is deeply oversold but may also indicate fundamental deterioration rather than a simple value opportunity. Recent momentum shows continued weakness, with the stock down -19.63% over the past 3 months and -0.63% over the past month, indicating that selling pressure has persisted even after the initial sharp decline. This short-term trend aligns with the longer-term downtrend, with no meaningful divergence to signal a reversal, as the stock remains 65.28% below its peak drawdown level. Key technical support is clearly defined at the 52-week low of $121.06, while resistance is far above at the 52-week high of $351.95. A breakdown below the $121 support could trigger another leg down, while any recovery would face immense overhead supply. The stock's beta of 0.554 indicates it has been significantly less volatile than the market during this decline, which is unusual for a stock in freefall and may suggest it is moving on company-specific, not systemic, risks.
Beta
0.55
0.55x market volatility
Max Drawdown
-65.3%
Largest decline past year
52-Week Range
$121-$348
Price range past year
Annual Return
-57.7%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | -1.1% | +4.9% |
| 3m | -21.9% | +0.6% |
| 6m | -21.8% | +5.1% |
| 1y | -57.7% | +28.8% |
| ytd | -17.3% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Revenue growth remains positive but is overshadowed by a severe profitability crisis; Q4 2025 revenue was $11.38 billion, representing 8.34% year-over-year growth, yet this was the lowest quarterly revenue in the provided data for 2025. The growth trajectory has been inconsistent, with revenue peaking in Q3 2025 at $11.48 billion before the Q4 dip. The company's profitability has collapsed dramatically, swinging from a net income of $298 million in Q1 2025 to a net loss of -$160 million in Q4 2025. Gross margin compressed severely to 6.16% in Q4 from a high of 11.48% in Q1, indicating intense pressure on medical cost ratios, which is critical for a managed care organization. The balance sheet and cash flow position have deteriorated alongside earnings; the company reported negative free cash flow of -$636 million on a TTM basis and an operating cash flow of -$298 million for Q4 2025. The debt-to-equity ratio of 0.97 indicates moderate leverage, but the current ratio of 1.69 suggests adequate short-term liquidity. However, the persistent negative cash generation raises concerns about the company's ability to fund operations internally without tapping its $4.25 billion cash balance or raising external capital.
Quarterly Revenue
$11.4B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$-636000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Given the company reported a net loss in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.194, which is exceptionally low and reflects the market's severe discounting of the revenue stream due to the profitability crisis. For context, the forward PE ratio is 16.85, but this is based on estimated future profitability which is highly uncertain given recent results. Compared to its own historical range, the current PS of 0.19 is near the bottom of its multi-year band, having fallen from levels above 2.0 in early 2024. This extreme compression signals the market is pricing in either a prolonged period of depressed margins or a fundamental impairment of the business model. The stock's valuation on an EV/EBITDA basis is 8.73, but this metric is less informative with Q4 EBITDA negative. The historical context is clear: the stock is trading at valuation multiples not seen in years, which could represent a deep value opportunity if the company can execute a turnaround, but currently prices in significant distress.
PE
18.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -14x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company's profitability has evaporated, with Q4 2025 net income at -$160 million and gross margin compressing over 500 basis points sequentially to 6.16%. This indicates a critical failure in managing medical costs, the core competency of a managed care organization. The negative free cash flow of -$636 million TTM, despite a $4.25 billion cash balance, raises a red flag about the business model's current viability. Revenue concentration in government Medicaid contracts (over 85% of members) exposes the company to regulatory and reimbursement rate risks, which may be materializing.
Market & Competitive Risks are elevated by the stock's valuation compression and sector dynamics. While the trailing PS ratio of 0.19 appears cheap, it may simply reflect a justified discount for a broken earnings model, not an opportunity. The stock's beta of 0.554, indicating lower volatility than the market during its 57% decline, suggests this is a company-specific crisis, not a broader sector sell-off. Competitive pressure from larger peers like UnitedHealth and Humana, who are benefiting from the same CMS payment increases, could exacerbate Molina's struggles to regain pricing power and member growth.
The Worst-Case Scenario involves a continuation of the Q4 2025 trends, where medical cost ratios remain elevated, leading to further quarterly losses, depletion of the cash balance, and potential credit rating downgrades. This could trigger a loss of state Medicaid contracts, a downward spiral in membership, and a liquidity crisis. Quantifying the downside, the stock could realistically retest and break its 52-week low of $121.06, representing a further -17% decline from the current price of $145.88. In a prolonged distress scenario, a drop to or below $100 is plausible, implying a total loss of over -30% from current levels.